Clinical Trial Details

Patients & Visitors
- Patients & Visitors
  At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
- Getting to UHN
- Emergency Departments
- COVID Information
- Virtual Care at UHN
- Accessibility at UHN
- Find a Doctor
- myUHN Patient Portal
- Health Information
- Patient & Family Learning Centres
- Caregiver Resource Hub
- Translation Services
- Patient Relations
- Patient Services
- Pay Your Bill
- Walk-Safe Program
Programs & Services
- Programs & Services
  Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
- Ajmera Transplant Centre
- Altum Health
- Centre for Mental Health
- Laboratory Medicine Program
- Krembil Brain Institute
- Joint Department of Medical Imaging
- Medicine Program
- Peter Munk Cardiac Centre
- Princess Margaret Cancer Centre
- Schroeder Arthritis Institute
- Surgery and Critical Care Program
- Toronto Rehab
- Integrated Care Program
- Social Medicine
- Women's Health Program
- Pharmacy Services
- Transplant Outpatient Pharmacy
- West Park Healthcare Centre
Health Professionals
- Health Professionals
  At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
- Refer a Patient to UHN
- Health Professions at UHN
- Observerships
Research at UHN
Education at UHN
- Education at UHN
  University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
- Michener Institute of Education
- UHN Education
- Health Information
- Patient & Family Learning Centres

About UHN
- About UHN
  University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
- Updates from the CEO
- UHN at a Glance
- Publications
- Our History
- Governance and Leadership
- Purpose and Performance
- Quality and Patient Safety
- Fiscal Accountability
- Privacy & Accessing Information
- Social Medicine Program
- Greening at UHN
- General Services
- Doing Business with UHN
- UHN Event Calendar
- UHN International
- Accessibility
Get Involved
- Ways You Can Help
  Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
- Volunteer
- Participate
- Donate
Newsroom
- Newsroom
  The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
- News Stories
- Media Releases
- UHN Podcasts
- Social Media at UHN
- Videos
- Media Contacts & Policies
TeamUHN
Careers
Contact

Summary
Eligibility & Details

For Patients:

Find out more about clinical trials, why they are done, how you can join a trial and what you can expect if you decide to take part in a trial.

Learn more about clinical trials

A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Description

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-520, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of NVL-520 in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of NVL-520 at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of NVL-520 in patients with advanced ROS1-positive NSCLC and other solid tumors.

View Eligibility & Trial Details >

https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx

Text Size

Last reviewed:

Last modified: 8/16/2023 10:09 AM

Back to Top